- The National Association of Attorneys General (NAAG) sent a letter on behalf of a bipartisan coalition of 38 state and territory AGs requesting that the FDA act to protect consumers from counterfeit forms of weight loss and diabetes drugs (GLP-1 drugs).
- In the letter, the AGs explain that counterfeit GLP-1 drugs have entered the U.S. supply chain from foreign sources and that these counterfeits can contain contaminants, other unknown drugs, or dangerously high amounts of active ingredients; that online retailers are illegally selling the active ingredients of GLP-1 drugs to consumers without a prescription, requiring consumers to formulate the medications themselves; and that unsanitary conditions at some pharmacies could lead to serious public health issues.
- The AGs argue that concurrent federal action will provide the most protection against illegal conduct related to the sale of GLP-1 drugs, and they urge the FDA to exercise its statutory authority through investigations, inspections, and enforcement actions.